Here are the 10-Q quarterly reports from Carisma Therapeutics Inc (CARM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CARM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CARM filings page.
Carisma Therapeutics (CARM) filed its Q3 report, highlighting a wind down strategy and going‑concern risk. The company reported $45.3 million in collaboration revenue in Q3, driven by recognition of deferred amounts and a $4.0 million one‑time payment from a September 16, 2025 amendment to its Moderna agreement. This produced net income of $44.7 million (EPS $1.07) for the quarter.
Cash and cash equivalents were $2.8 million as of September 30, 2025, and management stated substantial doubt about continuing as a going concern. Deferred revenue fell to zero from $45.0 million, total liabilities were $7.4 million, and stockholders’ deficit narrowed to $0.9 million.
The planned merger with OrthoCellix was terminated on September 16, 2025; Carisma recorded a $1.3 million receivable for a termination fee and expense reimbursement. Trading of its common stock on Nasdaq was suspended October 13, 2025, and shares now trade on the OTCID market. Carisma has ceased R&D, is pursuing asset monetizations, and is preparing an orderly wind down; it may file a Form 15 to suspend SEC reporting and notes it is unlikely a meaningful cash amount will be available for stockholder distribution.